anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

209,461-209,520 of 319,975

filter-aware
44
The slide uses a Venn diagram to illustrate target overlap and a tree diagram to show potential combination therapy paths.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
45
The slide uses a comparative framework to validate the efficacy of CDx-guided patient selection.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
46
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
47
The slide uses a grid layout for headshots and a logo cloud at the bottom.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
48
The slide uses a table-based timeline structure to map specific drug candidates (SPY001-004) to expected regulatory and clinical milestones.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
49
The chart uses a custom range bar (min/max) with markers for IPO and Today's market cap.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
50
The slide uses a timeline-based comparison to suggest that Spyre's assets are on a similar trajectory to high-value acquired assets.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
51
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
52
The slide serves as a credibility transfer by showcasing the partner's team and achievements.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
53
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
54
The slide uses a pentagon diagram to represent the five pillars of their antibody engineering platform.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
55
The diagram illustrates the mechanism of FcRn-mediated antibody recycling, contrasting physiological affinity with high affinity.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
56
Includes two distinct chart types: a scatter plot for half-life correlation and bar charts for ADA rates.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
01
Slide 1
Alkermes | Results Presentation Deck | 17 slidesAlkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Setup1 hit
02
Alkermes | Results Presentation Deck | 17 slidesAlkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Setup1 hit
03
Alkermes | Results Presentation Deck | 17 slidesAlkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Setup1 hit
04
Includes footnotes explaining the impact of Janssen arbitration on financial results.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Setup1 hit
05
Includes footnotes regarding arbitration and product definitions.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator Overview1 hit
06
The table includes a blue box highlighting the Q2 2023 column. Footnotes explain the impact of an arbitration settlement on Manufacturing & Royalty Revenue.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator Overview1 hit
07
Includes a disclaimer regarding the separation of the oncology business and a footnote about non-GAAP reconciliation.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator OverviewLoop · Cost Of Inaction1 hit
08
Alkermes | Results Presentation Deck | 17 slidesAlkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator OverviewLoop · Cost Of Inaction1 hit
09
The chart illustrates revenue diversification across four products: VIVITROL, ARISTADA, VUMERITY, and LYBALVI.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator OverviewLoop · Cost Of Inaction1 hit
10
The chart displays both weekly data and a 4-week rolling average.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator OverviewLoop · Cost Of Inaction1 hit
11
Alkermes | Results Presentation Deck | 17 slidesAlkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator OverviewLoop · Cost Of Inaction1 hit
12
The chart includes a vertical dashed line separating historical data from the most recent quarter.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator Overview1 hit
13
Alkermes | Results Presentation Deck | 17 slidesAlkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Key Performance Indicator Overview1 hit
14
Alkermes | Results Presentation Deck | 17 slidesAlkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Appendix1 hit
15
Alkermes | Results Presentation Deck | 17 slidesAlkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Appendix1 hit
16
The table includes specific line items for share-based compensation, depreciation, amortization, separation expenses, tax effects, non-cash interest, and a significant Janssen arbitration award.Alkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Appendix1 hit
17
Alkermes | Results Presentation Deck | 17 slidesAlkermes | Results Presentation Deck | 17 slides · Alkermes
Conference presentation Investor relations Beat · Closing Ask1 hit
01
Slide 1
argenx SE | Results Presentation Deck | 15 slidesargenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations 1 hit
02
argenx SE | Results Presentation Deck | 15 slidesargenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations 1 hit
03
The slide uses a corporate branding background with a network/molecular overlay.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations Beat · WhyLoop · Golden Circle1 hit
04
The slide uses a circular, iterative process diagram to represent the growth strategy.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations Beat · Key Messages1 hit
05
Kaplan-Meier survival curve showing probability of no relapse over 48 weeks.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations Beat · ProblemLoop · Before After1 hit
06
The slide uses a split-screen layout to contrast established proof-of-concept (left) with future development plans (right).argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations Beat · RoadmapLoop · Maturity Curve1 hit
07
The slide uses a bubble-based layout to display various brand and study logos centered around the main argenx corporate logo.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations 1 hit
08
Includes a callout for cash position at end of Q2 2023.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations Beat · KPIsLoop · Pareto Focus1 hit
09
The slide uses a 3D-like coordinate system to represent growth vectors.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations Beat · Roadmap1 hit
10
The slide uses a central circular image overlaying key performance indicators.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations 1 hit
11
argenx SE | Results Presentation Deck | 15 slidesargenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations Beat · Key Messages1 hit
12
The slide uses a map to visualize geographic reach, paired with two tables detailing approval timelines for two different products.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations 1 hit
13
The slide uses a patient story to humanize the clinical goals of minimizing burden and achieving sustained responses.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations 1 hit
14
The slide uses a process-oriented layout to show how strategic pillars are supported by specific operational achievements.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations Beat · Key TakeawaysLoop · So What Cascade1 hit
15
The diagram is a hub-and-spoke model representing corporate values.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations 1 hit
01
Slide 1
argenx SE | Results Presentation Deck | 16 slidesargenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations 1 hit
02
argenx SE | Results Presentation Deck | 16 slidesargenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations 1 hit
03
The slide uses a list-based layout to present three key clinical findings.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
04
The slide uses a high-level mission statement as the primary anchor for the presentation.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
05
The slide uses a central portrait of a patient (Crystal) to humanize the clinical data points surrounding her.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
06
The slide uses a spiral/funnel-like diagram to illustrate the compounding nature of patient challenges.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
07
The slide uses a process flow diagram to illustrate the patient journey through the trial, including specific durations and transition criteria.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
08
The table displays mean (SD) or n (%) for various clinical metrics including age, gender, diagnosis duration, and disease activity scores.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
09
The slide highlights efficacy across different patient subsets and mentions specific clinical metrics (INCAT, I-RODS, grip strength).argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
10
The slide uses a Kaplan-Meier plot to demonstrate clinical efficacy.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
11
The table includes hazard ratios, p-values, and mean changes from baseline for CIDP disease progression and functional scores.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
12
The slide presents clinical trial safety data for VYVGART Hytrulo.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
13
Uses a 'before-after' framing to contrast legacy treatments (IVIg, Steroids, PLEX) with the new product's benefits.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
14
The slide uses a bubble-based layout to showcase brand logos and study names centered around the corporate brand.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
15
The slide uses a three-column layout to categorize progress into Clinical, Regulatory, and Revenue pillars.argenx SE | Results Presentation Deck | 16 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit